Zobrazeno 1 - 10
of 54
pro vyhledávání: '"M H, Cullen"'
Autor:
A. Burton, E. L. Jones, J. A. Child, J. Glaholm, G. M. Smith, M. H. Cullen, A P Haynes, E M Bessell, Andrew Jack, Ian O. Ellis, J. M. Davies
Publikováno v:
Annals of Oncology. 14:258-267
Background The aim of this study was to determine in a randomised trial whether there is any significant difference in toxicity between modified CHOP and MCOP chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma (NHL) and to dete
Autor:
B W Hancock, W M Gregory, M H Cullen, G Vaughan Hudson, A Burton, P Selby, K A Maclennan, A Jack, E M Bessell, P Smith, D C Linch, Central Lymphoma Group
Publikováno v:
British Journal of Cancer
The purpose of this randomized trial was to compare the efficacy of 6 cycles of prednisolone, Adriamycin (doxorubicin), bleomycin, vincristine (Oncovin) and etoposide (PABlOE) with 3 cycles of PABIOE that alternate with 3 cycles of chlorambucil, vinb
Autor:
M H Cullen, S Nicum
Publikováno v:
Anti-Cancer Drugs. 11:603-607
Non-small cell lung cancer (NSCLC) is the world's leading cause of cancer death and about 75% of all patients have advanced disease incurable with localized treatments (surgery and radiotherapy) alone. The aims of therapy in these are palliation of s
Autor:
D. R. Norfolk, C. Stack, A. V. Simmons, Andrew Jack, C. M. Woodroffe, D. L. Barnard, N. P. Bailey, M. H. Cullen, John Fletcher, Janet A. Dunn, E. Bessell, J. Farish, Robert Grieve, N. S. A. Stuart, J. A. Child
Publikováno v:
Annals of Oncology. 9:633-638
Background: Weekly alternating regimen known as CAPOMEt is compared to standard cyclical chemotherapy (CHOP-Mtx) in aggressive non-Hodgkin's lymphoma (NHL). Patients and methods: Three hundred and eighty-one patients with aggressive NHL were randomis
Autor:
G. M. Smith, C. M. Woodruffe, D. L. Barnard, M. H. Cullen, John Fletcher, H. Earl, J. A. Child, N. P. Bailey
Publikováno v:
Hematological Oncology. 14:193-201
In a multi-centre phase I study we investigated the possibility of reducing the interval between courses of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 2 mgs day 1, and prednisolone 40 mg/m2 days 1-8) from 21 days to
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 21
Management of febrile neutropenia: ESMO Clinical Practice Guidelines J. de Naurois, I. Novitzky-Basso, M. J. Gill, F. Marti Marti, M. H. Cullen & F. Roila On behalf of the ESMO Guidelines Working Group* Department of Medical Oncology; Department of H
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 20
Publikováno v:
European Journal of Cardio-Thoracic Surgery. 5:519-522
Thirty-eight patients with localised oesophageal carcinoma have been studied by computed tomography (CT) and barium swallow before and after preoperative chemotherapy and the results correlated with the pathological findings in the resected specimen.
Autor:
S A, Hussain, D H, Palmer, D E, Swinson, P, Riley, A, Wills, C, Brown, C, Draycott, A, El-Modir, D R, Peake, D W, Rea, A D, Chetiyawardana, M H, Cullen
Publikováno v:
Oncology reports. 20(1)
In response to increasing pressure on inpatient services and a meta-analysis indicating that cisplatin (C) is superior to carboplatin, we report a phase II trial of gemcitabine (G) and split-dose C in advanced non-small cell lung cancer (NSCLC) in an
Autor:
M. Zereu, Petr Zatloukal, Sverre Sörenson, Silvia Novello, Patrick Peterson, Carla Visseren-Grul, M. H. Cullen, J. R. Fischer, Anil A. Joy, Neill Iscoe
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 19(5)
This phase III randomized trial compared pemetrexed 500 mg/m(2) (P500) with pemetrexed 900 mg/m(2) (P900) to determine whether higher dosing benefits non-small-cell lung cancer (NSCLC) patients as second-line therapy.Patients with locally advanced or